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Abstract
Background: Involvement of AFP against apoptosis of tumor cell has been implicated in its evasion
of immune surveillance. However, the molecular events of immune escape mechanisms are still
unknown. The major observations reported here relate to a possible mechanism by which
heptoloma Bel 7402 cells escape immune surveillance in vitro.
Methods: Western blotting and a well-characterized cofocal scanning image were performed to
analyze the expression of Fas/FasL and caspase-3 in co-cultured Bel 7402 and Jurkat cells.
Results: After co-culture with Jurkat cells, up-regulated Fas and reduced FasL expression could be
observed. Treatment with AFP could remarkably inhibit the elevated Fas and, whereas, induce the
FasL expression in co-cultured Bel 7402 cells. Cells co-culture could induce the expression of
caspase-3 in both cells line. The elevated caspase-3 in Bel 7402 cells was abolished following the
treatment of AFP. The expression of caspase-3 was elevated in co-cultured Jurkat cells treated with
AFP. No detectable change on the expression of survivin was examined in both cells line.
Monoclonal antibody against AFP treatment alone did not obviously influence the growth of cells,
as well as the expression of Fas/FasL and caspase-3. However, the effect of AFP could be blocked
by antibody.
Conclusions: our results provide evidence that AFP could promote the escape of liver cancer
cells from immune surveillance through blocking the caspase signal pathway of tumor cells and
triggering the Fas/FasL interaction between tumor cells and lymphocytes.
Background
Alpha fetoprotein (AFP) is one of several oncofetal pro-
teins synthesized in large amounts by the fetus and drops
in serum markedly shortly after birth. AFP as a tumor-
associated fetal protein has demonstrated clinical utility
as a tumor marker. Besides its role as a carrier or trans-
porter for various serum ligands including fatty acids,
retinoids, steroids, drugs, dyes and heavy metals, AFP has
been reported to display growth regulatory properties.
Previous studies have verified that AFP appears to func-
tions as a growth regulator rather than only serum carrier.
Multitude of cell types involving the growth and differen-
tiation effects of AFP include placental [1], lymphoid [2],
ovarian [3], uterine [4], gastric cancer [5], epidermal [6],
breast cancer [7] and fetal fibroblasts [8]. Recently, some
studies on the mechanisms of AFP suggested that AFP
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induced apoptosis in tumor cells independently of Fas/
Fas ligand or TNFR/TNF signaling pathway, and AFP-
mediated cell death involved activation of the effector cas-
pase-3-like proteases, but was independent of upstream
activation of the initiator caspase-1, caspase-8, and cas-
pase-9-like proteases [9]. The intracellular mechanism of
AFP involving to cAMP-PKA signaling pathway after its
binding to different affinity receptors has been also
reported [10].
Although the biological roles of the oncoembryonal pro-
tein AFP, including immunoregulatory functions in a vari-
ety of immune responses including the humoral and cell-
mediated types, have been reviewed in detail, the evi-
dences for the role of AFP in hepatoma cells escaping from
host immune surveillance are still unknown [11,12]. In a
recent study, AFP was used as an effective tumor rejection
antigen to observe its effect in T-cell immune responses,
implicating a gene therapy-based strategy for hepatoma
cells [13]. However, the over-expression of AFP in human
hepatoma cells is concurrent with aberrant growth mani-
festation. We presume that the altered serum AFP level is
the cause of such changes rather than a coincident phe-
nomenon and should be responsible for the malignant
progression of liver cancer. Thus revealing the intracellu-
lar mechanisms underlying the evasion of tumor from
host immune surveillance will provide further insights
into the understanding for the biological role of AFP, par-
ticularly in the case of hepatocellular carcinomas.
Methods
Determination of cells proliferation
Jurkat T cells and Bel 7402 cells, the human hepatoma cell
line, were adjusted to 3.0 × 104 per ml separately and
maintained in PRMI-1640 medium supplemented with
10% heat-inactivated fetal bovine serum. The cells were
seeded into 24-well plates and incubated at 37°C in a
humidified atmosphere of 5% CO2. The supernatant was
replaced to RPMI-1640 medium free serum for 24 h, then
the various concentrations (5, 10, 20, 40, 80 or 100 mg/L)
of AFP (Biodesign International Co. USA), human serum
albumin (HSA, from Sigma, USA) and anti-AFP antibody
(Santa Cruz. USA) were administrated into Jurkat T cells
and Bel 7402 cells for 60 h respectively. The viability of
cells was determined by Trypan blue exclusion assay.
Cell co-culture assay
To observe the effect of AFP on the escape of tumor cell
from the attack of lymphocytes, 1.5 × 104 of Jurkat calls
and equal Bel 7402 cells that grew under such conditions
were mixed and co-cultured onto 24-well plate. Following
the incubation in RPMI-1640 medium for 24 h, AFP (20
mg/L), HSA (20 gm/L), AFP (20 mg/L) plus anti-AFP anti-
body (40 mg/L) and anti-AFP antibody (40 mg/L) were
added into culture for 60 h. The fraction containing Jurkat
cells were removed from flask by resuspending the super-
natant gently and transferring the supernatant to a centri-
fuge tube. Bel 7402 cells in the bottom were scraped and
collected. The viability of each cell line was determined by
Trypan blue exclusion.
Determination of Fas and FasL expression
Bel 7402 cells and Jurkat T cells were co-cultured as
described above in Petri dish. AFP (20 mg/L), HSA (20
mg/L), AFP (20 mg/L) plus anti-AFP antibody (40 mg/L)
and anti-AFP antibody (40 mg/L) were added into culture.
At 48 hours treatment, Bel 7402 cells were washed 3 times
with RPMI-1640 free serum to remove Jurkat cells. Cells
were incubated with 0.5 ml of rabbit anti-Fas or anti-FasL
solution (Santa Cruz Co, USA. 1:250 in RPMI-1640
medium) for 1 h. After washing with medium 3 times at
room temperature, secondary goat anti-rabbit IgG anti-
bodies conjugated with FITC (Santa Cruz, USA) were
applied, and incubated for 1 hour at 37°C. After washing
with PBS, the cells were observed under Confocal Laser
Scanning Microscope (Leica TCS-NT SP2, Germany).
Western blot immunodetection
1.5 × 104 Jurkat T cells and 1.5 × 104 Bel 7402 cells per ml
were co-cultured in 75-cm2  flasks and maintained in
RPMI-1640 medium free serum for 24 h. To replace the
supernatant with medium supplemented with 10% FCS,
the supernatant which containing the Jurkat cells were
removed, centrifuged and resuspended with fresh
medium. The suspension was replaced into flasks to remix
with Bel 7402 cells. Afterward, the co-cultured cells were
treated with AFP (20 mg/L), HSA (20 gm/L), AFP (20 mg/
L) plus anti-AFP antibody (40 mg/L) and anti-AFP anti-
body (40 mg/L) for 36 h respectively. Proteins were quan-
tified before being loaded onto the gel. 40 µg of extracted
proteins from each group was loaded onto 10% SDS poly-
acrylamide gels. Proteins were blotted onto a nitrocellu-
lose membrane (Amersham, UK). Membranes were
incubated for 1 h with anti-caspase-3 or anti-survivin
monoclonal antibodies (Santa Cruz Co. USA) and then
washed and revealed using anti-rabbit IgG horseradish
peroxidase conjugate. Immunoreaction protein was
detected by the chemiluminescence luminol reagent
(Santa Cruz, USA).
Statistical analyses
All experiments were performed at least three times. Data
were presented as mean ± SD. The significance of the dif-
ference between experimental and control groups was
analyzed with Student's t test. A value of p < 0.05 was con-
sidered to be statistically significant.BMC Cancer 2005, 5:96 http://www.biomedcentral.com/1471-2407/5/96
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Results
The effects of AFP on the proliferation of cells
AFP could enhance the proliferation of Bel 7402 cells in
the dose-dependent manner in the concentration range of
10 to 80 mg/L (Fig 1A). The increment was up to 46.8%
(80 mg/L) compared with control. However, the inhibited
effect of AFP was observed in the growth of Jurkat cells.
The maximum suppressive dose might be observed at the
concentration of 80 mg/L (30.6% inhibition). As the con-
trols, HSA and anti-AFP antibody did not display any
detectable influences on the cell growth (Fig 1B and 1C).
The effects of AFP on the growth of co-cultured cells
To observe the effects of AFP on the escape of Bel 7402
cells from the attack of lymphocytes, AFP at a concentra-
tion of 20 mg/L, which has been reported and proved to
be an optimal dose according to the dose response curves
in our recent experiments [unpublished data], was added
into co-cultured cells. Jurkat and Bel 7402 cells were sep-
arated as described in Materials and Methods after the treat-
ment of 60 h and the viability of each cell was determined.
The results showed that the growths of both cells in
untreated group were inhibited in the cells co-culture (Fig
2). However, the administration of AFP could obviously
inhibit the proliferation of Jurkat cells, but not Bel 7402
cells after cells co-culture. Anti-AFP antibody could block
the effect of AFP on cell proliferation. Antibody alone and
HSA did not display any significant influences on the cell
growth.
Fas/FasL expression in Bel 7402
AFP was added into either separate-cultured or co-cul-
tured cells to observe its effects on the expression of Fas
and FasL in Bel 7402 under confocal fluorescent micro-
scope. As shown in Fig 5, untreated cells cultured sepa-
rately did not exhibit green fluorescence on the surface of
Bel 7402 (Fig 3A). After the administration of AFP for 48
h, only a diffuse image could be observed (Fig 3B). Bel
7402 cells co-cultured with Jurkat cells for 90 min exhib-
ited an ever-increasing green fluorescence throughout the
time course that reflected the presence of expressed Fas,
which was faded after the addition of AFP (Fig 3E and 3C).
Anti-AFP antibody alone did not change the fluorescent
intensity of image and however, could partly reverse the
effect of AFP on the expression of Fas (Fig 3D and 3F). In
the observation of FasL, separate-cultured Bel 7402 cells
did not display the expression of FasL (Fig 4A). The slight
green outline of cells was observed after the addition of
AFP (Fig 4B). The cell co-culture could induce the expres-
sion of FasL in Bel 7402 cells (Fig 4C). However, Bel 7402,
in contrast with that observed in the assay of Fas, co-cul-
tured with Jurkat cells in the presence of AFP could show
an enhanced green fluorescent. A representative image is
shown in Fig 4D.
The effects of different concentrations of AFP on the growth  of cells Figure 1
The effects of different concentrations of AFP on the growth 
of cells. The viability of Jurkat and Bel 7402 cells were 
observed after treated with different concentrations (5, 10, 
20, 40, 80 or 100 mg/L) of either AFP (A), anti-AFP antibody 
(B) or HSA (C) for 60 h at 37°C in a humidified atmosphere 
of 5% CO2. *P < 0.05 and **P < 0.01 vs corresponding to 
normal control (0 mg/L) analyzed by t-test. Data were repre-
sentative of an experiment that was repeated three times 
presented as mean ± SD of 12 samples.BMC Cancer 2005, 5:96 http://www.biomedcentral.com/1471-2407/5/96
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Immunodetection of apoptosis-related proteins
When different cells were separately cultured, AFP could
enhance the intracellular expression of caspase-3 in Jurkat
cells and suppress that in Bel 7402 cells (Fig 5). In the co-
culture experiment, the contents of caspase-3 in both cell
lines were increased even though no AFP treatment. As
shown by the intensities of the immuno-positive bands,
the synthesis of intracellular caspase-3 in Jurkat cells was
potently up-regulated after the administration of AFP. In
contrast, no detectable change in the content of caspase-3
could be observed in the co-cultured Bel 7402 cells, indi-
cating the block of AFP. The effect of AFP on the expres-
sion of caspase-3 in both cells could be abolished by anti-
AFP antibody. As shown in Fig 6, AFP did not display sig-
nificant influence on the level of survivin although a slight
increment in co-cultured Jurkat cells.
Discussion
During the last decade, it has been confirmed from a mul-
titude of studies that AFP as a growth regulator modulates
the ontogenic growth and tumor progression even though
the overall findings remain controversial and their inter-
pretations are still being debated. Previous studies also
implicated that AFP expressed during pregnancy inhibits
the maternal immune exclusion by suppressing immune
responses of the humoral and cell-mediated types [14].
The higher level of AFP in the serum of liver cancer subject
has been considered to be the reason of tumor develop-
ment rather than merely the concomitant oncofetal pro-
tein. Hereby, the implication was emerged that AFP
functions to constitute one of fundamental steps in the
progression of hepatoma. It is in fact that one of mecha-
nisms of progression and development of liver cancer is
due to its escaping from immune surveillance. Experimen-
tal results obtained from the present study showed that
AFP was capable of suppressing the growth of Jurkat cells
with the concomitant proliferation of Bel 7402, indicating
the diversity effects of AFP on the regulation of immune
and tumor cells growth. This result was supported by a
recent study, which indicated that AFP induced significant
apoptosis of dendritic cells [15]. AFP-treated dendritic
cells could produce low levels of IL-12 and TNF-α, a
cytokine pattern that could hamper an efficient antitumor
immune response. These results thereby offered a mecha-
nism by which hepatocellular carcinoma escapes immu-
nological control.
Co-culture experiment has been widely used for the deter-
mination of apoptosis, pathological response and tumor
related protein synthesis [16-18]. The effects of Fas/FasL
in the mechanism of tumor escaping from immune sur-
veillance have been extensively documented [19-22]. It
has been proposed that the expression of Fas/FasL in
tumors may play a critical role in immune escape. In the
present study, the expression of Fas/Fas L in target
hepatoma Bel 7402 cells was examined after co-culture
with the effector Jurkat cells in vitro. Our data showed that
the expression of membrane Fas was enhanced in Bel
7402 cells co-cultured with Jurkat cells. The fact that the
enhanced expression of Fas was abolished by AFP expo-
sure indicated that the stimulation of Jurkat cells to Bel
7402 cells was able to be blocked by AFP. This is in
accordance with our recent findings from immunodetec-
tion analysis (unpublished data). On the other hand, AFP
enhanced the synthesis of FasL in Bel 7402 cells, which
was consistent with previous findings [23-27]. AFP-
induced over-expression of Fas on the surface of lym-
phocytes, together with simultaneous over-secreted FasL
from tumor cells, could be one of reasons to accelerate the
death of lymphocytes and facilitate the immune escape of
liver cancer. This conclusion is supported by a recent
study, which indicated that Fas-mediated apoptosis
resulted by cancers expressing FasL and killing lym-
phocytes was irrespective of transforming growth factor-
beta1 (TGF-beta1) expression [28].
Although the precise mechanism of AFP-mediated cell
growth regulation and apoptosis induction remains
The effects of AFP on the co-cultured cells Figure 2
The effects of AFP on the co-cultured cells. Bel 7402 and Jur-
kat cells were co-cultured for 24 h following treated with 
AFP (20 mg/L) (C), AFP (20 mg/L) plus anti-AFP antibody (40 
mg/L) (D), anti-AFP antibody (40 mg/L) (E) and HSA (20 gm/
L) (F) respectively. Graph bar A represents the viability of 
separate-cultured cells. Graph bar B represents co-cultured 
and no-treatment group. After 60 h, two cell lines were sep-
arated and the viability of each cell was observed respec-
tively. *P < 0.05 and **P < 0.01 vs corresponding to normal 
control (0 mg/L) analyzed by t-test. Data were representative 
of an experiment that was repeated three times presented as 
mean ± SD of 12 samples.BMC Cancer 2005, 5:96 http://www.biomedcentral.com/1471-2407/5/96
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obscure, there have been considerable investigations indi-
cating that AFP can modulate apoptotic signals induced
by various factors by either promoting or abrogating
apoptosis. In the present study, the intracellular level of
caspase-3 in Bel 7402 cells after co-culture with Jurkat
cells was up-regulated, indicating the inducement of the
apoptotic protein by lymphocytes. Furthermore, the
pretreatment of AFP in vitro in co-cultured cells led to the
full abolishment of caspase-3. Whereas, an increment at
the level of caspase-3 protein was observed in co-cultured
Jurkat cells after stimulated by AFP, which resulted in the
depletion of lymphocytes in culture. The accelerated
death of lymphocytes in current study might serve to cer-
tify the speculation that AFP-mediated apoptosis involved
activation of the effector caspase-3-like proteases [9].
Therefore, it is reasonable to postulate that the escaping of
tumor cells from immune surveillance is partly attributa-
ble to the apoptosis of lymphocytes induced by AFP. Tak-
ing into consideration the ability of AFP to alter the Fas/
FasL expression in Bel 7402 and Jurkat cells, the signaling
pathway involved might be initiated through the interac-
tion of AFP with corresponding receptors and induced the
activation of Fas/FasL and caspase-3 system. Our data elu-
cidated that the death signal was triggered by activation of
specific membrane AFP receptors involved in apoptosis
signaling, leading to the expressional alteration of Fas/
FasL and caspase-3. These findings are in accordance with
the previous data showing that Fas/FasL was involved in
AFP-induced immune escape [29-31].
Conclusions
In summary, the present study has at least partly explained
demonstrated the potential effect of AFP in malignant
Confocal assay for the expression of Fas on the membrane of  co-cultured Bel 7402 cells Figure 3
Confocal assay for the expression of Fas on the membrane of 
co-cultured Bel 7402 cells. Bel 7402 cells and Jurkat T cells 
were co-cultured with AFP (20 mg/L), anti-AFP antibody (40 
mg/L), and AFP (20 mg/L) plus anti-AFP antibody (40 mg/L) 
respectively for 48 h. After removing Jurkat cells, Bel 7402 
cells were incubated with rabbit anti-Fas antibody and sec-
ondary goat anti-rabbit IgG antibodies conjugated with FITC. 
The cells were observed using a confocal laser scanning 
microscope. Image A: separate-cultured Bel 7402 cell; B: sep-
arate-cultured Bel 7402 cells treated with AFP; C: co-cul-
tured Bel 7402 cells treated with AFP; D: co-cultured Bel 
7402 cells treated with anti-AFP antibody. Right images from 
A to D were taken under common microscope to observe 
the state of cells. E: co-cultured Bel 7402 cells; F: co-cultured 
Bel 7402 cells treated with AFP and anti-AFP antibody. All 
images were representative of an experiment that was 
repeated three times.BMC Cancer 2005, 5:96 http://www.biomedcentral.com/1471-2407/5/96
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Confocal assay for the expression of FasL on the membrane of co-cultured Bel 7402 cells Figure 4
Confocal assay for the expression of FasL on the membrane of co-cultured Bel 7402 cells. Bel 7402 cells and Jurkat T cells 
were co-cultured with AFP (20 mg/L) for 48 h. After removing Jurkat cells, Bel 7402 cells were incubated with rabbit anti-FasL 
antibody and secondary goat anti-rabbit IgG antibodies conjugated with FITC. The cells were observed using a confocal laser 
scanning microscope. Image A: separate-cultured Bel 7402 cell; B: separate-cultured Bel 7402 cells treated with AFP. Right 
images of A and B were taken under common microscope to observe the state of cells. C: co-cultured Bel 7402 cells without 
AFP treatment; D: co-cultured Bel 7402 cells treated with AFP. All images were representative of an experiment that was 
repeated three times.BMC Cancer 2005, 5:96 http://www.biomedcentral.com/1471-2407/5/96
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growth and transformation of liver tumor cell. Take
together all findings, we propose that the effect of AFP in
the escape of hepatoma Bel 7402 cells from immune sur-
veillance is achieved though decreasing Fas in its mem-
brane and secreting FasL which in turn to trigger apoptosis
of lymphocytes via caspase-3 cascade. Thus, the involve-
ment of Fas- and caspase-related signal pathway in the
occurrence of liver tumor was thereby indicated in this
study. The precise elucidation of the biological effect of
AFP will help to better understand the regulatory mecha-
nism of immune surveillance in liver cancer.
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